Second generation antipsychotics are currently the drugs of choice for the treatment of schizophrenia and bipolar mania, as well as for behavioural symptoms in patients with dementia. All these diseases represent an important healthcare problem in Europe, so that early treatment is recommended. Due to improved patient compliance, new pharmaceutical forms of already proven therapy are developed. Orally disintegrated tablets